The Preliminary study of the Clinical outcome of using the PCSO-524 polyunsaturated fatty acid compound (Antinol) in the treatment of Canine Osteoarthritis and degenerative spinal diseases

The clinical outcome of PCSO-524 application in the treatment of canine osteoarthritis and spinal disorder was studied at the Small Animal Teaching Hospital, Chulalongkorn University.

Eighty-four dogs were included in our study. Thirty-one dogs showed signs of osteoarthritis (OA) in both hip joints and shoulder joints; 33 dogs had OA in stifle joints from cranial cruciate ligament rupture; and 20 dogs had neurological signs of the cauda equina syndrome.

All affected dogs were treated by 50 mg/ 10 kg of PCSO-524, PO for twelve weeks.


. . . VIEW

. . . VIEW

Updated Study Topics

New researches and publications related to PCSO-524® and its result in clnical test submitted by veterinarians on the global conferences every year and the data keeps growing with more studies conducted


Discover More Studies
Click to see the library